Discover
Rubraca (rucaparib) / ClovisClovis Oncology announces presentations at 2020 ASCO Virtual Scientific Program (Businesswire) - May 21, 2020 - "Clovis Oncology...announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca® (rucaparib) in multiple tumor types have been accepted for presentation or publication at the American Society of Clinical Oncology 2020 Virtual Scientific Program taking place May 29 – 31....The accepted abstracts summarize findings from clinical trials in which Rubraca was evaluated as a single-agent therapy in ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC) and malignant mesothelioma, and in combination with irinotecan in multiple advanced solid tumors, as well as findings from real-world evidence studies of the epidemiology and current treatment landscape of mCRPC."
dostarlimab (TSR-042) / GSK; GSK3377794 / GSK; Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaGSK highlights scientific innovation and advances in its growing oncology portfolio at ASCO 2020 (PRNewswire) - May 20, 2020 - "As part of its ongoing work to advance potentially transformational medicines, GlaxoSmithKline plc will present new data at the upcoming 2020 American Society of Clinical Oncology (ASCO) Annual Meeting from 29-31 May 2020. The depth and breadth of the presentations represent GSK's progress in helping people affected by cancer achieve better outcomes and build on the recent US Food and Drug Administration (FDA) approval of a new indication for Zejula® (niraparib)."
